Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes

[1]  J. Silverberg,et al.  Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies , 2021, Dermatitis : contact, atopic, occupational, drug.

[2]  J. Silverberg,et al.  Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. , 2021, The New England journal of medicine.

[3]  J. Silverberg,et al.  Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials , 2020, The Journal of dermatological treatment.

[4]  J. Silverberg,et al.  Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis , 2020, JAMA dermatology.

[5]  C. Flohr,et al.  Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis , 2020, JAMA dermatology.

[6]  H. Williams,et al.  Strengths and limitations of the United Kingdom Working Party criteria for atopic dermatitis in adults , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  J. Silverberg,et al.  Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate-to-severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 & SOLO 2, AD ADOL, and CHRONOS. , 2020, Journal of the American Academy of Dermatology.

[8]  S. Ständer,et al.  Characterizing treatment‐related patient needs in atopic eczema: insights for personalized goal orientation , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  E. Peeva,et al.  Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis , 2019, JAMA dermatology.

[10]  M. Ardeleanu,et al.  Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis† , 2019, The British journal of dermatology.

[11]  D. Margolis,et al.  Health Utility Scores of Atopic Dermatitis in US Adults. , 2019, The journal of allergy and clinical immunology. In practice.

[12]  D. Margolis,et al.  Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population. , 2019, The Journal of investigative dermatology.

[13]  J. Silverberg,et al.  Association between atopic dermatitis, depression, and suicidal ideation: A systematic review and meta-analysis. , 2019, Journal of the American Academy of Dermatology.

[14]  D. Margolis,et al.  Content and construct validity, predictors, and distribution of self-reported atopic dermatitis severity in US adults. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[15]  L. Skov,et al.  Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta‐analysis , 2018, Journal of the American Academy of Dermatology.

[16]  D. Margolis,et al.  Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[17]  J. Silverberg,et al.  Validation of patient‐reported global severity of atopic dermatitis in adults , 2018, Allergy.

[18]  J. Gelfand,et al.  Impact of atopic dermatitis on health‐related quality of life and productivity in adults in the United States: An analysis using the National Health and Wellness Survey , 2017, Journal of the American Academy of Dermatology.

[19]  J. Silverberg.  Public Health Burden and Epidemiology of Atopic Dermatitis. , 2017, Dermatologic clinics.

[20]  A. Gnanasakthy,et al.  Impact of Measuring Patient-Reported Outcomes in Dermatology Drug Development , 2017, The Patient - Patient-Centered Outcomes Research.

[21]  J. Silverberg,et al.  Association between Atopic Dermatitis and Depression in US Adults. , 2015, The Journal of investigative dermatology.

[22]  J. Schmitt,et al.  Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME) , 2014, The British journal of dermatology.

[23]  E. L. Sutton.  Psychiatric disorders and sleep issues. , 2014, The Medical clinics of North America.

[24]  N. Nicola,et al.  The molecular regulation of Janus kinase (JAK) activation. , 2014, The Biochemical journal.

[25]  C. Flohr,et al.  Psychological and educational interventions for atopic eczema in children. , 2014, The Cochrane database of systematic reviews.

[26]  J. Silverberg,et al.  Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. , 2013, The Journal of allergy and clinical immunology.

[27]  E. Simpson,et al.  Mental health comorbidity in patients with atopic dermatitis. , 2013, The Journal of allergy and clinical immunology.

[28]  J. Szepietowski,et al.  Relationship between itch and psychological status of patients with atopic dermatitis , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[29]  Fleur Fritz,et al.  Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. , 2012, Acta dermato-venereologica.

[30]  J. Schmitt,et al.  EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference , 2012, Allergy.

[31]  G. Bonsel,et al.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.

[32]  G. Bonsel,et al.  Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study , 2010, Quality of Life Research.

[33]  Jeffrey A. Johnson,et al.  Using Instrument-Defined Health State Transitions to Estimate Minimally Important Differences for Four Preference-Based Health-Related Quality of Life Instruments , 2010, Medical care.

[34]  T. Strine,et al.  The PHQ-8 as a measure of current depression in the general population. , 2009, Journal of affective disorders.

[35]  H. Williams,et al.  What are the best outcome measurements for atopic eczema? A systematic review. , 2007, The Journal of allergy and clinical immunology.

[36]  M. Oquendo,et al.  Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. , 2007, The American journal of psychiatry.

[37]  D. Cella,et al.  Measuring Fatigue for Children With Cancer: Development and Validation of the Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (pedsFACIT-F) , 2007, Journal of pediatric hematology/oncology.

[38]  H. Williams,et al.  The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. , 2004, Archives of dermatology.

[39]  R. Snaith,et al.  The Hospital Anxiety And Depression Scale , 2003, Health and quality of life outcomes.

[40]  Bruce G. Bender,et al.  Actigraphy assessment of sleep disturbance in patients with atopic dermatitis: An objective life quality measure , 2003 .

[41]  D. Cella,et al.  Fatigue in cancer patients compared with fatigue in the general United States population , 2002, Cancer.

[42]  A. Osman,et al.  The Suicidal Behaviors Questionnaire-Revised (SBQ-R):Validation with Clinical and Nonclinical Samples , 2001, Assessment.

[43]  M. Graeber,et al.  The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis , 2001, Experimental dermatology.

[44]  D. Cottrell,et al.  Validation of the Hospital Anxiety and Depression Scale for use with adolescents , 1999, British Journal of Psychiatry.

[45]  A Y Finlay,et al.  The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use , 1995, The British journal of dermatology.

[46]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[47]  A. Zbrozek,et al.  The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument , 1993, PharmacoEconomics.

[48]  Erika Sevetson,et al.  The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. , 2017, The Journal of investigative dermatology.

[49]  J. Silverberg,et al.  Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. , 2015, The Journal of investigative dermatology.

[50]  S. Ersser,et al.  Psychological and educational interventions for atopic eczema in children. , 2007, The Cochrane database of systematic reviews.

[51]  M. Graeber,et al.  The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. , 2001, Experimental dermatology.

[52]  D. Strachan,et al.  Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. , 1999, The Journal of allergy and clinical immunology.